959 Shares in Medpace Holdings, Inc. $MEDP Acquired by Curated Wealth Partners LLC

Curated Wealth Partners LLC purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 959 shares of the company’s stock, valued at approximately $599,000.

Several other institutional investors and hedge funds have also made changes to their positions in MEDP. HBW Advisory Services LLC boosted its stake in shares of Medpace by 33.9% during the third quarter. HBW Advisory Services LLC now owns 513 shares of the company’s stock worth $320,000 after buying an additional 130 shares during the period. Krilogy Financial LLC lifted its stake in shares of Medpace by 5.6% in the third quarter. Krilogy Financial LLC now owns 2,475 shares of the company’s stock valued at $1,535,000 after purchasing an additional 131 shares during the period. Steel Grove Capital Advisors LLC purchased a new stake in shares of Medpace during the 3rd quarter worth approximately $413,000. NorthCrest Asset Manangement LLC boosted its position in Medpace by 53.4% during the third quarter. NorthCrest Asset Manangement LLC now owns 997 shares of the company’s stock worth $601,000 after purchasing an additional 347 shares in the last quarter. Finally, GK Wealth Management LLC acquired a new stake in Medpace in the 3rd quarter valued at about $117,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on the company. TD Cowen lifted their price objective on Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $535.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Leerink Partners set a $620.00 price target on shares of Medpace in a research note on Thursday, July 23rd. UBS Group assumed coverage on shares of Medpace in a research note on Wednesday, September 30th. They set a “neutral” rating and a $673.00 price target on the stock. Finally, Robert W. Baird lifted their price target on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, Medpace currently has an average rating of “Hold” and a consensus price target of $607.73.

Medpace Stock Performance

Medpace stock opened at $618.47 on Friday. The firm has a market capitalization of $17.26 billion, a PE ratio of 36.85, a price-to-earnings-growth ratio of 2.80 and a beta of 1.18. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90. The stock’s 50 day moving average price is $606.41 and its 200 day moving average price is $532.06.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%. Medpace’s quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter last year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO August Troendle sold 21,966 shares of the firm’s stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $625.47, for a total value of $13,739,074.02. Following the sale, the chief executive officer directly owned 338,225 shares in the company, valued at $211,549,590.75. This trade represents a 6.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders have sold 336,140 shares of company stock valued at $208,008,328. Company insiders own 20.50% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.